glp-1 r retatrutide vs Semaglutide and Tirzepatide: GLP-3 Facts explained Retatrutide peptide for weight loss

At 48 weeks, weight loss was dose-dependent: the 12 mg group achieved approximately 24.2% mean weight loss, which was meaningfully higher than the approximately 15% reported for semaglutide 2.4 mg in the STEP 1 trial and approximately 20-22% for tirzepatide in the SURMOUNT trials

Solutions Focus on calorie-dense protein sources: fatty fish, whole eggs, higher fat dairy, protein powder Use liquid calories strategically: protein shakes, smoothies, milk digest more easily than solid food Time higher calorie meals for windows when appetite is strongest (often morning for many users) Consider dose reduction if appetite suppression is preventing adequate nutrition Set phone reminders to eat every 3 hours regardless of hunger signals Challenge: Energy Fluctuations Affecting Training Some users experience periods of reduced energy, particularly during early adaptation or immediately following dose increases

Importantly, GLP-1 receptor agonists are not indicated for type 1 diabetes or diabetic ketoacidosis

A.GerberK